A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker in newly diagnosed glioblastoma (GBM).

Stephen J. Bagley,Seyed Ali Nabavizadeh,Jacob Till,Aseel Abdalla,Hareena Sanga,Jazmine Mays,Timothy Prior,Andrew Jurgielewicz,Samantha Guiry,Karapet Davtyan,Stephanie S. Yee,Zev A. Binder,Donald M. ORourke,Steven Brem,Arati Desai,Erica L. Carpenter

A prospective validation cohort study of baseline plasma cell-free DNA (cfDNA) as a prognostic biomarker in newly diagnosed glioblastoma (GBM).

2020

Stephen J. Bagley
Seyed Ali Nabavizadeh
Jacob Till
Aseel Abdalla
Hareena Sanga
Jazmine Mays
Timothy Prior
Andrew Jurgielewicz
Samantha Guiry
Karapet Davtyan
Stephanie S. Yee
Zev A. Binder
Donald M. ORourke
Steven Brem
Arati Desai
Erica L. Carpenter

2508Background: Due to significant interpatient heterogeneity, survival outcomes vary widely in patients with GBM. Novel prognostic biomarkers are needed. We aimed to determine the prognostic impac...

Keywords:

validation cohort
Plasma cell
Oncology
free dna
Glioblastoma
Internal medicine
Pathology
newly diagnosed
Medicine
prognostic biomarker
in patient
Biomarker (medicine)

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations